Tang R - Search Results

1

Cost analysis of S1 and XELOX as adjuvant therapy for gastric cancer.

He J, Wen F, Yin X, Zhang P, Du Z, He X, Zhou Y, Tang R, Li M, Li Q. He J, et al. Among authors: tang r. Anticancer Drugs. 2013 Aug;24(7):754-8. doi: 10.1097/CAD.0b013e328361bef2. Anticancer Drugs. 2013. PMID: 23629479

2

Cost-effectiveness analysis of colon cancer treatments from MOSIAC and No. 16968 trials.

Wen F, Yao K, Du ZD, He XF, Zhang PF, Tang RL, Li Q. Wen F, et al. World J Gastroenterol. 2014 Dec 21;20(47):17976-84. doi: 10.3748/wjg.v20.i47.17976. World J Gastroenterol. 2014. PMID: 25548497 Free PMC article.

3

Which is false: oxaliplatin or fluoropyrimidine? An analysis of patients with KRAS wild-type metastatic colorectal cancer treated with first-line epidermal growth factor receptor monoclonal antibody.

Wen F, Tang R, Sang Y, Li M, Hu Q, Du Z, Zhou Y, Zhang P, He X, Li Q. Wen F, et al. Among authors: tang r. Cancer Sci. 2013 Oct;104(10):1330-8. doi: 10.1111/cas.12224. Epub 2013 Jul 30. Cancer Sci. 2013. PMID: 23822592 Free PMC article.

4

Cost-effectiveness analysis of gemcitabine, S-1 and gemcitabine plus S-1 for treatment of advanced pancreatic cancer based on GEST study.

Zhou J, Zhao R, Wen F, Zhang P, Tang R, Du Z, He X, Zhang J, Li Q. Zhou J, et al. Among authors: tang r. Med Oncol. 2015 Apr;32(4):121. doi: 10.1007/s12032-015-0580-4. Epub 2015 Mar 19. Med Oncol. 2015. PMID: 25788034 Clinical Trial.

5

Cost-effectiveness of sorafenib as a first-line treatment for advanced hepatocellular carcinoma.

Zhang P, Yang Y, Wen F, He X, Tang R, Du Z, Zhou J, Zhang J, Li Q. Zhang P, et al. Among authors: tang r. Eur J Gastroenterol Hepatol. 2015 Jul;27(7):853-9. doi: 10.1097/MEG.0000000000000373. Eur J Gastroenterol Hepatol. 2015. PMID: 25919775

6

Cost-effectiveness of RAS screening before monoclonal antibodies therapy in metastatic colorectal cancer based on FIRE3 Study.

Wen F, Yang Y, Zhang P, Zhang J, Zhou J, Tang R, Chen H, Zheng H, Fu P, Li Q. Wen F, et al. Among authors: tang r. Cancer Biol Ther. 2015;16(11):1577-84. doi: 10.1080/15384047.2015.1095398. Epub 2015 Sep 29. Cancer Biol Ther. 2015. PMID: 26418570 Free PMC article.

7

Cost-effectiveness analysis of treatments for metastatic pancreatic cancer based on PRODIGE and MPACT trials.

Zhou J, Zhao R, Wen F, Zhang P, Wu Y, Tang R, Chen H, Zhang J, Li Q. Zhou J, et al. Among authors: tang r. Tumori. 2016 Jun 2;2016(3):294-300. doi: 10.5301/tj.5000499. Epub 2016 Apr 5. Tumori. 2016. PMID: 27056335

8

Economic evaluation study (CHEER-compliant): Cost-effectiveness analysis of RAS screening for treatment of metastatic colorectal cancer based on the CALGB 80405 trial.

Zhou J, Zhao R, Wen F, Zhang P, Tang R, Chen H, Zhang J, Li Q. Zhou J, et al. Among authors: tang r. Medicine (Baltimore). 2016 Jul;95(27):e3762. doi: 10.1097/MD.0000000000003762. Medicine (Baltimore). 2016. PMID: 27399059 Free PMC article.

9

Vesicular stomatitis virus is a potent agent for the treatment of malignant ascites.

Zhou Y, Wen F, Zhang P, Tang R, Li Q. Zhou Y, et al. Among authors: tang r. Oncol Rep. 2016 Mar;35(3):1573-81. doi: 10.3892/or.2015.4522. Epub 2015 Dec 24. Oncol Rep. 2016. PMID: 26707610

10

The role of tiopronin for the prevention of chemotherapy-related liver toxicity in advanced colorectal cancer patients treated with mFOLFOX7: a prospective analysis.

Li XP, Wen F, Yang W, Deng YB, Li M, Zhang PF, Tang RL, Li Q, Wei YQ. Li XP, et al. Tumori. 2014 Jul-Aug;100(4):446-51. doi: 10.1700/1636.17908. Tumori. 2014. PMID: 25296595

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

5,398 results

Search Page

Filters